For the year ending 2025-12-31, ZNTL had $2,094K increase in cash & cash equivalents over the period. -$125,247K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -137,060 |
| Depreciation and amortization | 739 |
| Operating lease right-of-use and fixed asset impairment | 4,136 |
| Noncash consideration portion of zentera in-process research and development | 0 |
| Share-based compensation | 20,722 |
| Goodwill impairment | 0 |
| (gain)/loss on disposal of equipment | 660 |
| Non-cash impact of revenues from licensing and sales of intellectual property | 0 |
| Non-cash recognized mark-to-market of equity securities | 1,239 |
| Accretion of discounts on marketable securities, net | 2,763 |
| Loss on equity method investment | 0 |
| Deferred income taxes | 0 |
| Deconsolidation of kalyra | 0 |
| Accounts receivable | -5,000 |
| Prepaid expenses and other assets | -2,993 |
| Accounts payable and accrued liabilities | -17,316 |
| Operating lease right-of-use assets and liabilities, net | 201 |
| Net cash used in operating activities | -125,247 |
| Purchases of marketable debt securities | 139,488 |
| Proceeds from maturities of marketable debt securities | 250,000 |
| Proceeds from sale of marketable equity securities | 20,413 |
| Proceeds from sale of property and equipment | 698 |
| Purchases of property and equipment | 0 |
| Net cash provided by (used in) investing activities | 131,623 |
| Proceeds from issuance of common stock, net | 5,390 |
| Proceeds from issuance of common stock under equity incentive plans | 304 |
| Repurchase of common stock | 9,976 |
| Net-settlement of restricted stock unit vesting | 0 |
| Net cash (used in) provided by financing activities | -4,282 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 2,094 |
| Cash, cash equivalents and restricted cash at beginning of year | 36,528 |
| Cash, cash equivalents and restricted cash at end of year | 38,622 |
Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL)